These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1039 related articles for article (PubMed ID: 33632153)

  • 1. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Humans PET Imaging of
    Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
    J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
    Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
    Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
    Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
    Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
    Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
    [No Abstract]   [Full Text] [Related]  

  • 9. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
    Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
    ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
    Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
    J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
    Garcia BNC; van Kempen LC; Kuijpers CCHJ; Schuuring E; Willems SM; van der Wekken AJ
    Lung Cancer; 2022 May; 167():1-7. PubMed ID: 35349855
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Bajjou T; Sekhsokh Y; Benmokhtar S; Jafari M; Baba W; Oukabli M; El Annaz H; Abi R; Tagajdid MR; El Kochri S; Lahlou IA; Ameziane El Hassani R; Ennibi K
    Cancer Control; 2024; 31():10732748241262179. PubMed ID: 38875469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
    Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
    Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of
    Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
    JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of
    Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
    JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
    Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
    Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer.
    Ounissi D; Weslati M; Boughriba R; Hazgui M; Bouraoui S
    Turk J Med Sci; 2021 Feb; 51(1):148-158. PubMed ID: 32892548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.